Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCL8 | P10145 | 2/20 | 0.56 |
| ▸ | SLC1A5 | Q15758 | 1/20 | 0.55 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.44 |
| ▸ | CAMK2A | Q9UQM7 | 2/20 | 0.43 |
| ▸ | FABP4 | P15090 | 1/20 | 0.43 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.43 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.42 |
| ▸ | CFD | P00746 | 1/20 | 0.42 |
| ▸ | PLG | P00747 | 1/20 | 0.42 |
| ▸ | PLAU | P00749 | 1/20 | 0.42 |
| ▸ | F11 | P03951 | 1/20 | 0.42 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.42 |
| ▸ | F7 | P08709 | 1/20 | 0.42 |
| ▸ | TPSB2 | P20231 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7679043 | 0.86 | SLC1A5 (0.54) | CXCL8SLC1A5CHRM1KDM4EL3MBTL1 | |
| SCHEMBL7698957 | 0.84 | CXCL8 (0.59) | CXCL8CHRM1KDM4ECYP1A2MAPT | |
| SCHEMBL18906064 | 0.84 | CXCL8 (0.52) | CXCL8SLC1A5CHRM1KDM4ECYP1A2 | |
| SCHEMBL11097326 | 0.81 | CXCL8 (0.79) | CXCL8CHRM1L3MBTL1AKR1B1CAMK2A | |
| SCHEMBL6827514 | 0.80 | KDM4E (0.51) | SLC1A5KDM4EP2RX4PDE4APDE4B | |
| SCHEMBL5023935 | 0.80 | KDM4E (0.51) | SLC1A5KDM4EMAPTL3MBTL1PDE4A | |
| SCHEMBL8827687 | 0.80 | CHRM1 (0.59) | CXCL8CHRM1L3MBTL1AKR1B1CAMK2A | |
| SCHEMBL8827625 | 0.80 | CXCL8 (0.51) | CXCL8CHRM1KDM4ECYP1A2MAPT | |
| SCHEMBL9799643 | 0.79 | L3MBTL1 (0.56) | SLC1A5KDM4EL3MBTL1TDP1 | |
| SCHEMBL8186213 | 0.79 | CYP4A11 (0.51) | CXCL8KDM4ECYP1A2MAPTAKR1B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6372766-B1 | FUNGICIDES AND ANTIGROWTH AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 2002-04-16 | — | — | US | claimed |
| US-20080287441-A1 | ALPHA-(TRIFLUOROMETHYL-SUBSTITUTED ARYLOXY, ARYLAMINO, ARYLTHIO OR ARYLMETHYL)-TRIFLUOROMETHYL-SUBSTITUTED PHENYLACETIC ACIDS AND DERIVATIVES AS ANTIDIABETIC AGENTS | METABOLEX, INC. (US) | 2008-11-20 | — | — | US | disclosed |
| US-7371888-B2 | α-(Trifluoromethyl-substituted aryloxy, arylamino, arylthio or arylmethyl)-trifluoromethyl-substituted phenylacetic acids and derivatives as antidiabetic agents | METABOLEX, INC. (US) | 2008-05-13 | — | — | US | disclosed |
| EP-1716116-A1 | ALPHA-(TRIFLUOROMETHYL-SUBSTITUTED ARYLOXY, ARYLAMINO, ARYLTHIO OR ARYLMETHYL)-TRIFLUOROMETHYL-SUBSTITUTED PHENYLACETIC ACIDS AND DERIVATIVES AS ANTIDIABETIC AGENTS | METABOLEX, INC. (US) | 2006-11-02 | — | — | EP | disclosed |
| US-20050222213-A1 | Alpha(trifluoromethyl-substituted aryloxy, arylamino, arylthio or arylmethyl)-trifluoromethyl-substituted phenylacetic acids and derivatives as antidiabetic agents | METABOLEX, INC. (US) | 2005-10-06 | — | — | US | disclosed |
| WO-2005080340-A1 | ALPHA-(TRIFLUOROMETHYL-SUBSTITUTED ARYLOXY, ARYLAMINO, ARYLTHIO OR ARYLMETHYL)-TRIFLUOROMETHYL-SUBSTITUTED PHENYLACETIC ACIDS AND DERIVATIVES AS ANTIDIABETIC AGENTS | METABOLEX, INC. (US) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222213-A1 | Alpha(trifluoromethyl-substituted aryloxy, arylamino, arylthio or arylmethyl)-trifluoromethyl-substituted phenylacetic acids and derivatives as antidiabetic agents | GPR119, SLC5A1, AADAC | CXCL8 4171/4885SLC1A5 172/4885CHRM1 2986/4885 |
| US-20080287441-A1 | ALPHA-(TRIFLUOROMETHYL-SUBSTITUTED ARYLOXY, ARYLAMINO, ARYLTHIO OR ARYLMETHYL)-TRIFLUOROMETHYL-SUBSTITUTED PHENYLACETIC ACIDS AND DERIVATIVES AS ANTIDIABETIC AGENTS | SLC5A1, GPR119, SLC5A2 | CXCL8 4168/4885SLC1A5 184/4885CHRM1 3002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.